1519.1 - Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma

Page last updated: 31 May 2019

Application Detail



Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).

Reason for Application


Medical Service Type

Hybrid health technology

Previous Application Number


Associated Documentation

Application Form


Consultation Survey

Feedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1519.1 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).

PICO Confirmation


Assessment Report


Public Summary Document


Meetings for this Application




13 June 2019